Amneal Launches Amicar Rival With CGT Exclusivity
Also Introduces US Rivals To Revatio And Carafate
After receiving FDA approval for its generic aminocaproic acid with 180 days of exclusivity under the agency’s Competitive Generic Therapy pathway, Amneal has launched the rival to Amicar. At the same time, it has also begun selling a generic version of Revatio and has also claimed the first generic rival to Carafate.
